Otonomy - Top 15 Biotech VC Deals of 2010

Company: Otonomy
Based: San Diego
Amount: $49.07M

Investors: Novo Ventures, Avalon Ventures, RiverVest Venture Partners, Domain Associates, and TPG Biotech.

Scoop: Otonomy closed a $38.5 million Series B financing last August. Novo Ventures and RiverVest Venture Partners co-led the round with help from Domain Associates and TPG Biotech. Otonomy had earlier in the summer raised $10 million. 

Otonomy's lead product is OTO-104. This sustained-release steroid is being evaluated in a Phase Ib trial as a treatment for Meniere's disease, a condition that can affect hearing and balance. The developer also is working on OTO-203, a combination product for middle ear infections.

Otonomy - Top 15 Biotech VC Deals of 2010

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.